Regentis Biomaterials Stock Falls Premarket After 506% Surge on Scrapped Share Offering

Regentis Biomaterials Ltd. shares turned lower in early Tuesday trading after a huge Monday rally that was driven by the removal of a near-term share-sale overhang. RGNT closed June 15 at $9.40, up 506.45% on the day, before Google Finance showed the stock indicated at $6.80 in premarket trading, down 27.66%. The same quote page listed an intraday high of $15.50, a low of $1.69 and a market capitalization of about $48.69 million, underscoring how thinly traded small-cap biotech and medtech names can swing sharply when news changes the supply-demand picture for shares.

16 June 2026

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials shares were quoted at $1.28 before the New York open on Tuesday, down 2 cents from their previous close, after the Israeli regenerative-medicine company set out the next step in its European launch plan for GelrinC, its knee cartilage repair implant.

9 June 2026